Dr. Burris on Using Recurrence Scores to Predict pCR

Howard A "Skip" Burris, III, MD
Published: Thursday, Feb 23, 2012

Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses the correlation between pathological complete response (pCR) and Oncotype DX recurrence scores (RS).

A phase II study that examined ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer patients found that patients with a high RS (greater than 31) or rapidly proliferating tumors responded better to chemotherapy, with 26% demonstrating a pCR. None of the patients in the trial with a low to intermediate RS experienced pCR.

The trial demonstrated that rapidly proliferating tumors are more susceptible to chemotherapy. Biologics may make a difference and still needs to be explored further in future clinical trials.
 
Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses the correlation between pathological complete response (pCR) and Oncotype DX recurrence scores (RS).

A phase II study that examined ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer patients found that patients with a high RS (greater than 31) or rapidly proliferating tumors responded better to chemotherapy, with 26% demonstrating a pCR. None of the patients in the trial with a low to intermediate RS experienced pCR.

The trial demonstrated that rapidly proliferating tumors are more susceptible to chemotherapy. Biologics may make a difference and still needs to be explored further in future clinical trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x